” As the clinical utility of NIPT is indisputable, weve focused on publishing real-world evidence evaluating the financial implications,” stated Ammar Qadan, Vice President and Global Head of Market Access at Illumina. “This research study, and other efforts, emphasize how payers can offer NIPT access to all pregnant women and produce much better results at about the same expense.”
Following the ACOG modification, a number of payers, such as UHC and Aetna, updated their protection policies to match these standards. Given the results from this study, its most likely that even more payers will do the same and broaden NIPT cover to ladies under 35.
Still, no public information existed for what occurs when coverage is opened up to more youthful women. Illumina and HPHC, which covers around 3 million people in the Northeastern United States, entered into a first-of-its-kind agreement in 2018 to open NIPT coverage for all pregnant, single gestation women under 35.
” These outcomes were the finest possible outcome,” said Michael Sherman, MD, MBA, MS, and Chief Medical Officer for the combined organization of Harvard Pilgrim Health Care and Tufts Health Plan. “We are happy to be on the cutting edge of precision medicine and in supplying favored access for our members to diagnostic tests that can enhance their lives.
In August 2020, the American College of Obstetricians and Gynecologists (ACOG) updated their clinical practice standards, suggesting NIPT for all pregnant females, despite age.
The outcomes of risk-sharing agreements involving business companies are not always revealed, and this research study intended to deal with that absence of openness. Illumina and HPHC engaged a third-party academic collaborator to develop a research study protocol, complete the analyses, and lead the publication advancement. The PharmacoEconomics article is the first-ever published manuscript on a value-based agreement between a bio/medical technology company and a payer.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has actually established us as the international leader in DNA sequencing and array-based technologies, serving consumers in the research, clinical, and applied markets. Our items are used for applications in the life sciences, oncology, reproductive health, farming, and other emerging sections. To get more information, go to www.illumina.com and get in touch with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.
” Our findings reveal that broadening NIPT coverage to women under 35 increased NIPT use and decently increased prenatal screening expenses,” stated R. Brett McQueen, PhD, associate teacher at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences and corresponding author on the paper. “This increased use recommends doctors and patients might choose a more precise screening approach.”
SAN DIEGO–( BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN), in addition to scientists at the University of Colorado and Harvard Pilgrim Health Care (HPHC), reported study outcomes assessing the effect of an innovative risk-sharing arrangement that opened insurance protection of non-invasive prenatal screening (NIPT) for pregnant women under the age of 35. Through this partnership, thousands of females accessed to NIPT and the financial effect was very little. The research study revealed broadening NIPT services just increased HPHCs costs by less than 3 cents per member per month. The study was released on March 11 in the open gain access to journal PharmacoEconomics.
Usage of forward-looking statements
SAN DIEGO–( BUSINESS WIRE)– Illumina, Inc. (NASDAQ: ILMN), along with researchers at the University of Colorado and Harvard Pilgrim Health Care (HPHC), reported study outcomes examining the impact of an innovative risk-sharing arrangement that opened insurance coverage of non-invasive prenatal testing (NIPT) for pregnant ladies under the age of 35. Through this collaboration, thousands of ladies got access to NIPT and the financial effect was very little. The study revealed expanding NIPT services just increased HPHCs costs by less than 3 cents per member per month. This release contains positive statements that include risks and unpredictabilities, consisting of the expectation that extra payers expand NIPT coverage to females under 35. Among the crucial elements that could cause actual outcomes to vary materially from those in any positive declarations is our ability to show the benefit of NIPT to payers and federal government companies, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most current filings on Forms 10-K and 10-Q, or in info divulged in public conference calls, the date and time of which are released beforehand.
This material was initially released here.
Media: Dr. Karen Birmingham
EMEA: +44 7500 105665.
United States: 646.355.2111.
kbirmingham@illumina.com.
This release includes positive declarations that involve unpredictabilities and risks, consisting of the expectation that additional payers broaden NIPT protection to females under 35. Amongst the essential aspects that could cause real outcomes to vary materially from those in any forward-looking statements is our ability to demonstrate the benefit of NIPT to payers and federal government firms, together with other elements detailed in our filings with the Securities and Exchange Commission, including our latest filings on Forms 10-K and 10-Q, or in information disclosed in public teleconference, the date and time of which are launched in advance. We undertake no commitment, and do not plan, to update these forward-looking declarations, to examine or validate experts expectations, or to supply interim reports or updates on the progress of the present quarter.
